About us
Inicure AB is a spinoff from the autoimmunity-focused company Pronoxis AB.
The company is developing anti-infectious assets activating the formyl peptide receptor-1 (FPR1) and was founded in 2024 by Peter Olofsson-Sahl, Sara Malcus, Johan Bylund, and GU Ventures AB.
Team

Peter Olofsson-Sahl
Preclinical drug development and international project management, founder of several innovative research companies

Sara Malcus
Business development and investment management. Extensive experience in the management of life science start-up companies, from CEO and Board positions.

Johan Bylund
Immunology and infections, including targeting of immunological mechanisms
Partners


Academic collaborators

NATIONWIDE CHILDREN’S HOSPITAL- Kidney and Urinary Tract Research Center
In a research collaboration with Dr. Juan de Dios Ruiz-Rosado and Dr. Brian Becknell within the Kidney and Urinary Tract Research Center at Nationwide Children’s Hospital, Columbus Ohio – we are jointly studying the immunological mechanism of the role of NOX inhibition as a mechanism for treatment of diseases of the kidney and urinary tract.
In this research project led by Dr. Juan de Dios Ruiz-Rosado, we are exploring the potential anti-bacterial properties of Pronoxis FPR specific agonists as potential novel agents to treat urinary tract infections (UTI).


SWANSEA UNIVERSITY -Medicine, health and life science
In a research collaboration with Dr Heather Chick and Professor Helen Griffiths within the faculty of Medicine, Health and Life science at Swansea University – we are jointly studying the role of FPR/NOX2 activation as a new way to combat and treat infections.
In this collaborative research project that is also part of the EU-funded project Neutrocure, we are exploring the potential anti-bacterial properties of Inicures FPR-specific agonists where the research performed at Swansea University is validating the anti-infective effects using in vitro cell models to identify and validate also biomarker and the immunological mechanisms of activation of the innate immune system with Inicures, FPR1 agonists.